1. Describe why plasma and PET biomarkers alone are insufficient for forecasting when an asymptomatic individual will decline.
  2. Explain how purpose-built, low-burden memory tests — especially in combination with blood biomarkers — can identify those most likely to decline and make trials more efficient.
  3. Discuss emerging evidence that diffusion-weighted imaging can reflect tau and amyloid pathology as a lower-burden alternative to PET.
Session date: 
10/09/2026 - 12:00pm to 1:00pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Craig Stark, PhD